Cimeio Therapeutics develops gene-editing technologies that create shielded hematopoietic stem cells (HSCs) to protect healthy cells during immunotherapy for leukemic tumors and autoimmune diseases. This approach enhances the safety and efficacy of hematopoietic stem cell transplants and adoptive cell therapies by preventing depletion of healthy cells while targeting diseased ones.
Funding
$50.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Immunotherapies for hematologic disorders often damage healthy hematopoietic stem cells (HSCs) along with diseased cells, leading to complications and limiting treatment efficacy. Current approaches lack the precision to selectively target malignant cells while sparing healthy tissue, hindering the potential of curative therapies.
Solution
Cimeio Therapeutics is developing Shielded-Cell and Immunotherapy Pairs (SCIPs), a technology platform designed to protect healthy HSCs during immunotherapy for hematologic malignancies and other disorders. The approach involves gene editing HSCs to make them resistant to depletion by paired immunotherapies, such as antibodies, T-cell engagers, antibody-drug conjugates (ADCs), and CAR-T cells. This shielding allows for safer and more effective administration of immunotherapies, boosting engraftment and treating minimal residual disease by selectively eradicating diseased cells while preserving healthy hematopoiesis. The company's epitope editing technology modifies cell surface receptors to prevent antibody binding without compromising receptor function.
Target Audience
The primary target audience includes patients with hematologic malignancies and other hematologic disorders who are candidates for immunotherapy, as well as clinicians and researchers in the fields of hematology, oncology, and gene therapy.
Features
- Gene editing of HSCs to insert novel protein variants that shield cells from depletion.
- Shielding technology effective against antibodies, T-cell engagers, ADCs, and CAR-T cells.
- Epitope editing to prevent antibody binding while maintaining receptor functionality.
- Paired immunotherapies designed to selectively deplete diseased cells.
- Potential to boost engraftment and treat minimal residual disease.